Drugs / Compound Realgar Formula Realgar-Indigo Naturalis
Compound Realgar Formula Realgar-Indigo Naturalis
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01755325 | Nov 2012 → Dec 2018 | chronic myeloid leukemia | Junmin Li | Suspended | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Compound Realgar Formula Realgar-Indigo Naturalis | “It is an open-label, randomized, double blind, placebo-controlled parallel-group, multi-center study to evaluate the efficacy and safety of Compound realgar formula...” NCT01755325 ↗ |
| Known as | Compound realgar formula Realgar-Indigo naturalis Tablet | “It is an open-label, randomized, double blind, placebo-controlled parallel-group, multi-center study to evaluate the efficacy and safety of Compound realgar formula...” NCT01755325 ↗ |
| Known as | Compound realgar natural indigo Tablet | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01755325 ↗ |